Tag
psychedelic news
- UBC psychedelics conference attracts multidisciplinary crowd with a shared passion
- Algernon partners with Yale University for phase II DMT study
- Psychedelic drugs market awaits nearly 100% revenue expansion by 2026 end: Fairfield
- European Psychiatric Association aligns with PAREA: a multi-organization psychedelic partnership
- ASKP3 Patient Portal to offer accurate fact-based info on ketamine
- Alberta pioneers psychedelic therapy regulations in Canada
- Numinus develops psilocybin-infused tea bag for clinical studies
- Choose Ketamine now offering at‑home treatments in several states
- Silo Pharma prepares pre‑IND package for FDA on novel ketamine formulation
- Vancouver mushroom dispensaries continue to operate in legal grey area
- Psilocybin and cannabis improve breast cancer treatment efficacy: Grace Health
- Irwin Naturals acquires Ketamine Media platform
- Psyence sends psilocybin mushrooms to Psilo Pharma in Portugal
- Cybin acquires license for psychedelic molecules from Mindset
- PsyCan pushes federal policy-makers to lift restrictions on psychedelics
- Numinus launches ketamine-assisted therapy in Toronto
- MindMed doses first patient with MDMA-like compounds in new trial
- ATMA receives Health Canada approval for new psilocybin trial
- MindMed re‑establishes Nasdaq listing requirements
- Delix gets recognized as leading start‑up by Nature Biotechnology
- DOSED 2 screening sells out at Vancouver's Rio Theatre
- Algernon receives approval to conduct DMT study in the Netherlands
- Optimi makes history with gargantuan psilocybin harvest
- San Fran lawmakers motion to decriminalize psychedelic plants
- Xtalks to host upcoming webinar on psychedelic know‑how
- Psychedelic use rising as the market expands: MicroSmallCap
- Field Trip facilitates beneficial psychedelic-assisted therapy for cancer patient
- Filament administers psilocybin to 14 participants in Health Canada sanctioned clinical trial
- Heroic Hearts collaborates with Maya to streamline psychedelic data for veterans
- PharmAla Biotech to provide University of Sydney with LaNeo MDMA for clinical studies
- Mindset Pharma discovers 3 novel next‑gen psychedelic compounds
- Beond publishes 'Ibogaine: A Clinical Summary'
- Cybin administers psychedelic analogue to patients with major depression
- PharmAla Biotech applies for patent on 6 novel MDMA-like molecules
- Clearmind's psychoactive drug shows positive results for cocaine use disorder
- MindMed announces initial patient dosing in MM‑120 study
- Cannabis and psychedelic use among young people reaches all‑time high in 2021: NIH
- Mind Medicine Australia receives AUD$1M grant for psychedelic research
- PharmAla Biotech becomes first public company producing GMP MDMA
- 'Hallucinogen' use continues to rise: Columbia University
- Phillips Lytle announces the inception of its Psychedelic & Mental Health Therapies Practice
- Cybin receives Schedule I DEA license for CYB003 trial
- Reunion Neuroscience starts trading on the TSX
- Optimi receives amendment from Health Canada permitting MDMA production
- Short Wave and Sheba partner for clinical trial aimed at combatting anorexia
- Lobe Sciences partners with iNGENū for new clinical trials in Australia
- Serenus Global becomes Health Canada licensed psilocybin distributor
- Sisters in Psychedelics host inaugural summit in Vancouver this September
- PharmAla Biotech initiates MDMA supplier agreement with InterVivo
- WITHIN 'Ceremonial Psychedelic Treatment Center' opens in Texas